Offering genetic testing to patients with myeloma would help doctors spot those with the most aggressive forms of the disease so that their cancer can be targeted more effectively, say scientists. 

With effective treatment, more than half of myeloma patients will survive their disease for five years or more.  

However, 20-25% have specific genetic changes in their cancer cells that make the disease more aggressive and harder to treat. High-risk patients typically see their disease come back much earlier after diagnosis, unless given tailored treatment. 

Now, new research led by The Institute of Cancer Research (ICR), London, and The University of Leeds has shown that patients who carry two or more genetic abnormalities – known as ‘double hit’ myeloma – are at more than twice the risk of their disease progressing early and almost three times more likely to die earlier with current standard treatment. 

The findings, published in the Journal of Clinical Oncology, have highlighted the high level of unmet need in this group of patients, and led to calls for better access to early genetic testing and personalised treatments. 

High-Risk Cytogenetic Abnormalities

There are typically around five or six key genetic changes, known as High-Risk Cytogenetic Abnormalities (HRCAs) that are used to classify myeloma as high risk. 

The new study was actively supported by many international myeloma study groups from Germany, Holland, Italy and Spain and industry partners. 

The researchers carried out a systematic review of 24 randomised controlled trials of myeloma around the world in which data about HRCAs was included, over a 20-year period.  

When the teams collated and analysed these results involving in total 13,926 patients, they showed for the first time that patients with two or more HRCAs were 2.28 times as likely to experience early disease progression than the control group (who had no HRCAs), regardless of the specific type of standard care treatment.  

Those with one HRCA were around 1.51 times more likely to experience early disease progression as the control group. 

They also found that patients with two or more HCRAs were 2.94 times more likely to die from the disease early, compared with the control group, while patients with one HRCA were 1.69 times more likely to die early. 

Tailored treatment improves survival

The study reinforces that some high-risk patients need better, tailored approaches than current standard therapies. 

Evidence that tailored approaches can help patients with ‘double hit’ myeloma live longer was shown in the OPTIMUM MUK 9 trial, co-led by The ICR, The University of Leeds and The Royal Marsden NHS Foundation Trust.  

OPTIMUM MUK 9 was the first trial in the world to use state-of-the-art diagnostics to screen for high-risk myeloma, and to offer personalised treatment for those patients identified to have the greatest need at the same time. 

The results of the trial showed that an intensive treatment regime of five drugs along with a stem cell transplant, kept the cancer at bay three times longer and doubled survival time for high-risk patients. 

Study leader Professor Martin Kaiser, Professor in Molecular Haematology at The ICR, London, and Consultant Haematologist at The Royal Marsden NHS Foundation Trust, said: “Myeloma is a very complex cancer. While current treatments can work very well for many people, there are others who do not respond well and may relapse early. The results of this study have enabled us to more accurately classify the aggressiveness of an individual patient’s cancer. We would like all myeloma patients to be able to access the newer diagnostic tests which enable clinicians to group individual patients based on their risk profile and provide treatment that is tailored to their needs. 

“We have already shown through the OPTIMUM trial that a more personalised approach involving five different existing drugs could help treat patients with the highest-risk forms of myeloma – helping keep them alive and healthy for longer.”

Diana Spencer, Senior Digital Content Editor, DDW